Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Iran Biomed J ; 23(2): 92-8, 2019 03.
Article in English | MEDLINE | ID: mdl-29986553

ABSTRACT

Background: Studies have revealed a strong association between mutations of CFTR gene and the congenital bilateral absence of the vas deferens (CBAVD), but the role of this gene in other types of male infertility is still unclear. The purpose of this study was to investigate the frequency of the most common mutations of the CFTR gene (DF508, G542X, N1303K, G551D, and W1282X) in a population of infertile men with nonobstructive azoospermia (NOA) and CBAVD in Iran. Methods: Blood samples were obtained from 50 NOA, 50 CBAVD, and 100 normal males (control). Genomic DNA was isolated from whole blood leukocytes, and the presence of common mutations of the CFTR gene was assessed by an amplification refractory mutation system-polymerase chain reaction (ARMS-PCR). Restriction fragment length polymorphism (PCR-RFLP) was also used to analyze IVS8-Tn polymorphism. Results: It was found that 16%, 8%, and 8% of patients with CBAVD were heterozygote for DF508, G542X, and N1303K, respectively. The frequency of the 5T allele was 34% and higher than the normal group (p < 0.001). None of the common CFTR gene mutations were detected in NOA patients, and no significant difference was found in the distribution of the 5T allele between the NOA patients and the control group (5 vs. 3 p = 0.721). Conclusion: Based on the present case-control study, the CFTR gene mutations and IVS8-Tn polymorphisms are correlated with CBAVD; however, extensive investigations are necessary to determine the exact relationship between the gene mutations and other forms of male infertility.


Subject(s)
Azoospermia/genetics , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Infertility, Male/genetics , Male Urogenital Diseases/genetics , Mutation/genetics , Polymorphism, Genetic/genetics , Vas Deferens/abnormalities , Azoospermia/diagnosis , Azoospermia/epidemiology , Case-Control Studies , Humans , Infertility, Male/diagnosis , Infertility, Male/epidemiology , Iran/epidemiology , Male , Male Urogenital Diseases/diagnosis , Male Urogenital Diseases/epidemiology , Population Surveillance/methods
2.
Cell Cycle ; 13(5): 801-6, 2014.
Article in English | MEDLINE | ID: mdl-24401334

ABSTRACT

The endoplasmic reticulum (ER)-resident protein kinase PERK is a major component of the unfolded protein response (UPR), which promotes the adaptation of cells to various forms of stress. PERK phosphorylates the α subunit of the translation initiation factor eIF2 at serine 51, a modification that plays a key role in the regulation of mRNA translation in stressed cells. Several studies have demonstrated that the PERK-eIF2α phosphorylation pathway maintains insulin biosynthesis and glucose homeostasis, facilitates tumor formation and decreases the efficacy of tumor treatment with chemotherapeutic drugs. Recently, a selective catalytic PERK inhibitor termed GSK2656157 has been developed with anti-tumor properties in mice. Herein, we provide evidence that inhibition of PERK activity by GSK2656157 does not always correlate with inhibition of eIF2α phosphorylation. Also, GSK2656157 does not always mimic the biological effects of the genetic inactivation of PERK. Furthermore, cells treated with GSK2656157 increase eIF2α phosphorylation as a means to compensate for the loss of PERK. Using human tumor cells impaired in eIF2α phosphorylation, we demonstrate that GSK2656157 induces ER stress-mediated death suggesting that the drug acts independent of the inhibition of eIF2α phosphorylation. We conclude that GSK2656157 might be a useful compound to dissect pathways that compensate for the loss of PERK and/or identify PERK pathways that are independent of eIF2α phosphorylation.


Subject(s)
Adenine/analogs & derivatives , Antineoplastic Agents/pharmacology , Eukaryotic Initiation Factor-2/metabolism , Indoles/pharmacology , Protein Kinase Inhibitors/pharmacology , eIF-2 Kinase/metabolism , Adenine/pharmacology , Adenine/therapeutic use , Animals , Cell Death/drug effects , Cell Line , Endoplasmic Reticulum Stress/drug effects , Humans , Indoles/therapeutic use , Mice , Phosphorylation , eIF-2 Kinase/antagonists & inhibitors
3.
J Androl ; 32(4): 367-70, 2011.
Article in English | MEDLINE | ID: mdl-21127309

ABSTRACT

Genetic factors including Y chromosome microdeletions and androgen receptor (AR) gene mutations are responsible for male infertility. In the present study, genetic analysis was performed in an infertile Iranian male with azoospermia. Multiplex polymerase chain reaction with 6 sequence-tagged site markers on the Yq11 chromosome revealed no microdeletions in the Y chromosome. Single-strand conformational polymorphism and sequencing analyses detected a 1510C→A transversion in exon 1 of the AR gene, which resulted in a p.Pro504Thr substitution in the transactivation domain of the protein. The present study suggested that mutations in the AR gene might be responsible for some cases of idiopathic infertility, and therefore, molecular analyses may be useful for genetic counseling of candidates with regard to the use of assisted reproductive techniques.


Subject(s)
Azoospermia/genetics , Receptors, Androgen/genetics , Sertoli Cell-Only Syndrome/genetics , Adult , Amino Acid Substitution , Humans , Male
4.
Indian J Med Res ; 132: 265-70, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20847372

ABSTRACT

BACKGROUND & OBJECTIVES: Genetic factors contribute about 10 per cent of male infertility. Among these, genes in azoospermia factor (AZF) region including AZFa, AZFb, AZFc and AZFd on the long arm of Y chromosome are considered most important for spermatogenesis. Deletions in these regions are thought to be involved in some cases of male infertility associated with azoospermia or oligozoospermia. We studied the incidence of AZF deletions among Iranian infertile men with idiopathic non-obstructive azoospermia. METHODS: A total of 100 Iranian azoospermic infertile men were selected for the molecular study of Y chromosome microdeletions. The presence of 13 sequence tagged site (STS) markers from AZF region was investigated using multiplex polymerase chain reaction (M-PCR). One hundred fertile men were also studied as control group. RESULTS: Twelve (12%) patients showed Y chromosome microdeletions and among these, deletion in AZFb region was the most frequent (66.67%) followed by AZFc (41.67%), AZFd (33.33%) and AZFa (8.33%), respectively. INTERPRETATION & CONCLUSIONS: Because of relatively high incidence of Y chromosome microdeletions among Iranian azoospermic patients, molecular screening may be advised to infertile men before using assisted reproductive treatments.


Subject(s)
Azoospermia/epidemiology , Azoospermia/genetics , Chromosome Deletion , Chromosomes, Human, Y/genetics , Seminal Plasma Proteins/genetics , Case-Control Studies , DNA Primers/genetics , Genetic Loci , Humans , Iran/epidemiology , Male , Polymerase Chain Reaction , Sequence Tagged Sites
5.
Cell Mol Neurobiol ; 27(3): 329-34, 2007 May.
Article in English | MEDLINE | ID: mdl-17186363

ABSTRACT

1. Alzheimer's disease (AD) is the most common form of dementia in the elderly in which interplay between genes and the environment is supposed to be involved. Mitochondrial DNA (mtDNA) has the only noncoding regions at the displacement loop (D-loop) region that contains two hypervariable segments (HVS-I and HVS-II) with high polymorphism. mtDNA has already been fully sequenced and many subsequent publications have shown polymorphic sites, haplogroups, and haplotypes. Haplogroups could have important implications to understand the association between mutability of the mitochondrial genome and the disease.2. To assess the relationship between mtDNA haplogroup and AD, we sequenced the mtDNA HVS-I in 30 AD patients and 100 control subjects. We could find that haplogroups H and U are significantly more abundant in AD patients (P = 0.016 for haplogroup H and P = 0.0003 for haplogroup U), Thus, these two haplogroups might act synergistically to increase the penetrance of AD disease.


Subject(s)
Alzheimer Disease/genetics , DNA, Mitochondrial/genetics , Genetic Predisposition to Disease , Haplotypes/physiology , Penetrance , Aged , Case-Control Studies , Female , Humans , Male , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...